X
<

What Drove Eli Lilly in 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 5
What Drove Eli Lilly in 3Q17? PART 5 OF 12

How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing

Trajenta revenue trends

In 3Q17, Eli Lilly’s (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Trajenta generated revenues of $68.4 million and $84.9 million, respectively, compared to $47.9 million and $67.5 million in 3Q16.

Trajenta reported revenues of $408.2 million in the first nine months of 2017. In YTD (year-to-date) September 2017, in the US and international markets, Trajenta reported revenues of $174.2 million and $234.1 million, respectively. Trajenta, a dipeptidyl peptidase-4 (or DPP-4) inhibitor, competes with Merck’s Januvia.

How Eli Lilly&#8217;s Trajenta, Trulicity, and Basaglar Are Performing

Interested in AZN? Don't miss the next report.

Receive e-mail alerts for new research on AZN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Trulicity revenue trends

In 3Q17, Trulicity reported revenues of $527.7 million compared to $243.6 million in 3Q16. In 3Q17, Trulicity witnessed 10% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Trulicity generated revenues of $412.9 million and $114.8 million, respectively, compared to $188.7 million and $54.9 million in 3Q16.

Trulicity reported revenues of $1.4 billion in the first nine months of 2017. $1.1 billion of this came from US markets, and $290.7 million came from international markets. In the antidiabetes drugs market, Trulicity competes with Novo Nordisk’s (NVO) Victoza, Sanofi’s (SNY) Lyxumia, and AstraZeneca’s (AZN) Byetta.

Basaglar revenue trends

In 3Q17, Basaglar reported revenues of $145.7 million compared to $19.4 million in 3Q16. In 3Q17, Basaglar witnessed ~68% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Basaglar generated revenues of $115.2 million and $30.5 million, respectively.

Basaglar reported YTD September 2017 revenues of $278.3 million. Basaglar generated YTD September 2017 revenues of $196.7 million and $81.6 million, respectively, from the US and international markets. In the antidiabetes drugs market, Basaglar faces stiff competition from Sanofi’s Lantus.

The revenue growth of Eli Lilly’s antidiabetic portfolio is expected to boost the share prices of the Vanguard S&P 500 ETF (VOO). Eli Lilly makes up about ~0.32% of VOO’s total portfolio holding.

X

Please select a profession that best describes you: